Put Options Advised as NYSE:JNJ Miss Sales Forecast

Put Options Advised as NYSE:JNJ Miss Sales Forecast

 
It’s not a pretty picture for Johnson & Johnson (NYSE:JNJ) as the company faces headwinds lately from both a fundamental and a technical picture.

On the fundamental side, the strong dollar is cited to be the reason for the recent decline in sales, as otherwise sales would have printed a positive number. Company representatives are saying that 4.5% is the negative dollar impact on its sales. Well, taking that into account together with the fact that the Federal Reserve is about to raise rates, so an even more stronger dollar to come, it means no good news for JNJ in the medium term.

On the fundamental side, recent news and scandals regarding patents seem to be endless as company was ordered by regulators to pay settlements in trials in the United States. The amount in case is not a big one but settles a trend which seems to have no end for the moment.

To the above add the fact that JP Morgan downgraded the stock early 2015 and this puts a negative view on it.

However, above all, the technical picture ahead of Fed rate hike seems to be the big problem.

Failing to stay above the 100 level brings into question the 2014 lows around $96.78 as the whole move since then was corrective and implications are that market will break it.

Therefore, current prices at $99.53 seem to be a good opportunity to buy put options with an expiration date that should stretch beyond Fed March meeting as this should bring levels lower than the 2014 October $96.78.


Related Articles

Pressure on Gross Margin Turns United Natural Bearish

  The shares of United Natural Foods, Inc. (NASDAQ:UNFI), the leading US distributor of organic foods, has risen about 18%

Pfizer Rallies on Rumour of Bristol-Myers Acquisition

  Last month, biopharmaceutical company Pfizer Inc (NYSE: PFE) reported a 12% y-o-y decline in the 4Q16 non-GAAP earnings to

Chesapeake Energized by Retention of Credit Line

  The share price of oil and natural gas producer Chesapeake Energy Corp (NYSE:CHK) rose 34.44% to $6.05 on Tuesday.